Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments

[at noodls] – Contract Manufacturing Revenue Expected to Exceed $18 Million for Fiscal Year 2013; Company Reaches Agreement With FDA on Pivotal Phase III Clinical Trial Design for Cotara; Multiple Bavituximab Clinical … more

View todays social media effects on PPHM

View the latest stocks trending across Twitter. Click to view dashboard

See who Peregrine is hiring next, click here to view